UK biotech industry booms on record investment – analysisUK biotech is booming, with the number of R&D companies increasing 65% since 2016 amid soaring annual investment Share XUK biotech industry booms on record investment – analysishttps://pharmaphorum.com/news/uk-biotech-industry-booms-on-record-investment-analysis/
Alexion signs R&D deals with two Nordic biotechsAlexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs. Share XAlexion signs R&D deals with two Nordic biotechshttps://pharmaphorum.com/news/alexion-signs-rd-deals-with-two-nordic-biotechs/
AI drug R&D company Exscientia signs deal with CelgeneUK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, Share XAI drug R&D company Exscientia signs deal with Celgenehttps://pharmaphorum.com/news/ai-drug-rd-company-exscientia-signs-deal-with-celgene/
Merck and Pfizer stop third Bavencio ovarian cancer trialMerck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share XMerck and Pfizer stop third Bavencio ovarian cancer trialhttps://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
Novo Nordisk files GLP-1 diabetes pill in the USNovo Nordisk has filed its oral formulation of diabetes drug semaglutide in the US, armed with a priority Share XNovo Nordisk files GLP-1 diabetes pill in the UShttps://pharmaphorum.com/news/novo-nordisk-files-glp-1-semaglutide-in-the-us/
France’s Doctolib is new digital health unicornDoctolib, the largest digital health service in Europe, has raised 150 million euros in a funding round, valuing Share XFrance’s Doctolib is new digital health unicornhttps://pharmaphorum.com/news/frances-doctolib-is-new-digital-health-unicorn/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
UK pharma patents up 20%, new report findsThe pharma industry saw double-digit growth in patent filings for the second year in a row in 2018, Share XUK pharma patents up 20%, new report findshttps://pharmaphorum.com/news/uk-pharma-patents-up-20-new-report-finds/
Seven future blockbuster drugs to look out for in 2019AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch Share XSeven future blockbuster drugs to look out for in 2019https://pharmaphorum.com/news/seven-future-blockbuster-drugs-to-look-out-for-in-2019/
Boehringer files for new rare disease use for nintedanib in EU, USBoehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, Share XBoehringer files for new rare disease use for nintedanib in EU, UShttps://pharmaphorum.com/news/boehringer-files-for-new-rare-disease-use-for-nintedanib-in-eu-us/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
AZ backs diabetes drug Farxiga with new cardio analysisAstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes Share XAZ backs diabetes drug Farxiga with new cardio analysishttps://pharmaphorum.com/news/az-backs-diabetes-drug-farxiga-with-new-cardio-analysis/
Cell Mogrify gets £420k funding for regenerative cell therapiesUK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven Share XCell Mogrify gets £420k funding for regenerative cell therapieshttps://pharmaphorum.com/news/cell-mogrify-gets-420k-funding-for-regenerative-cell-therapies/
Lixiana hits the mark in catheter ablation trialDaiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker Share XLixiana hits the mark in catheter ablation trialhttps://pharmaphorum.com/news/lixiana-hits-the-mark-in-catheter-ablation-trial/
Allergy Therapeutics suffers phase 3 birch allergy jab trial failureUK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest Share XAllergy Therapeutics suffers phase 3 birch allergy jab trial failurehttps://pharmaphorum.com/news/allergy-therapeutics-suffers-phase-3-birch-allergy-jab-trial-failure/
Karuna raises $68m to develop neurology drug KarXTKaruna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 Share XKaruna raises $68m to develop neurology drug KarXThttps://pharmaphorum.com/news/karuna-raises-68m-to-develop-neurology-drug-karxt/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
10 Key Reasons to attend SMi’s 2nd Annual Pharmaceutical Microbiology East Coast Share X10 Key Reasons to attend SMi’s 2nd Annual Pharmaceutical Microbiology East Coasthttps://pharmaphorum.com/partner-content/10-key-reasons-to-attend-smis-2nd-annual-pharmaceutical-microbiology-east-coast/
Conference Chair from MedinCell invites you to attend Injectable Drug Delivery Conference Share XConference Chair from MedinCell invites you to attend Injectable Drug Delivery Conferencehttps://pharmaphorum.com/partner-content/conference-chair-from-medincell-invites-you-to-attend-injectable-drug-delivery-conference/
Robust Approaches to Advance Pre-Filled Syringe Development Share XRobust Approaches to Advance Pre-Filled Syringe Developmenthttps://pharmaphorum.com/partner-content/robust-approaches-to-advance-pre-filled-syringe-development/
Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019 Share XInterview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019https://pharmaphorum.com/partner-content/interview-released-with-reckitt-benckiser-speaker-at-pain-therapeutics-2019/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
